109 related articles for article (PubMed ID: 26113782)
1. PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy.
Zhang C; Li A; Li H; Peng K; Wei Q; Lin M; Liu Z; Yin L; Li J
Mediators Inflamm; 2015; 2015():417184. PubMed ID: 26113782
[TBL] [Abstract][Full Text] [Related]
2. [Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
Peng K; Lin M; Wei Q; Li H; Zhang C; Xie R; Liu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1111-4. PubMed ID: 26616804
[TBL] [Abstract][Full Text] [Related]
3. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
[TBL] [Abstract][Full Text] [Related]
5. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
Madbouly KM; Hussein AM; Zeid A
Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
[TBL] [Abstract][Full Text] [Related]
7. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
[TBL] [Abstract][Full Text] [Related]
8. Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.
Osumi H; Shinozaki E; Suenaga M; Wakatsuki T; Nakayama I; Matsushima T; Ogura M; Ichimura T; Takahari D; Chin K; Nagasaki T; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Yamaguchi K
PLoS One; 2017; 12(5):e0176745. PubMed ID: 28562679
[TBL] [Abstract][Full Text] [Related]
9. Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy.
Mejri N; Dridi M; Labidi S; El Benna H; Daoud N; Boussen H
Clin Transl Oncol; 2017 Dec; 19(12):1524-1530. PubMed ID: 28589428
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
[TBL] [Abstract][Full Text] [Related]
12. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Kaneko M; Nozawa H; Sasaki K; Hongo K; Hiyoshi M; Tada N; Murono K; Nirei T; Kawai K; Sunami E; Tsuno NH; Kitayama J
Oncology; 2012; 82(5):261-8. PubMed ID: 22538399
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
16. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
17. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Mirakhorli M; Rahman SA; Abdullah S; Vakili M; Rozafzon R; Khoshzaban A
Mol Med Rep; 2013 Feb; 7(2):613-7. PubMed ID: 23232902
[TBL] [Abstract][Full Text] [Related]
19. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer.
Nakayama I; Suenaga M; Wakatsuki T; Ichimura T; Ozaka M; Takahari D; Shinozaki E; Chin K; Ueno M; Mizunuma N; Yamaguchi T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):133-9. PubMed ID: 25994854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
